Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on March 27, 2007, regarding an event that occurred on March 22, 2007. The filing addresses the authorization of a new executive compensation plan by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation arrangements rather than financial performance results.
Material Changes
The primary material change reported is the implementation of the Executive Stock Option Bonus Plan for 2007. Under this plan, executive officers are eligible to receive annual bonuses in the form of common stock options based on the achievement of individual and corporate objectives. Additional awards are available for performance exceeding annual individual objectives.
Maximum Stock Option Awards (2007)
| Name and Position | Maximum Stock Option Award |
|---|---|
| John M. Maraganore, Ph.D. (President and CEO) | 40,000 |
| Barry E. Greene (Chief Operating Officer) | 21,900 |
| Patricia L. Allen (Vice President of Finance and Treasurer) | 12,500 |
Guidance, Outlook, and Terms
- Grant Timing: Options are expected to be granted in December 2007 at a regularly scheduled Board meeting.
- Exercise Price: Will equal the fair market value of the common stock on the date of grant.
- Vesting Schedule: 25% of shares vest on the first anniversary of the grant date, followed by an additional 6.25% at the end of each successive three-month period until the fourth anniversary.
- Adjustments: Awards are subject to adjustment in the event of a stock split or similar event.
Investor Verification Checklist
- Verify the specific corporate and individual performance objectives written by the Committee that determine eligibility for the 2007 awards.
- Confirm the actual grant date and exercise price in December 2007 filings.
- Monitor future filings for the actual number of options granted versus the maximum potential awards listed.
- Review the Company's stock price history to assess the potential dilution impact of these option grants.